Review Article

Cognitive Impairment in Genetic Parkinson’s Disease

Table 2

Studies assessing cognitive function in Parkin-associated PD.

ParticipantsType of studyCognitive measuresFindings

Luking et al. [61]101 Parkin-EOPD (≤45 years)Cross-sectionalMMSENo significant differences
85 EOPD noncarriers
Alcalay et al. [64]43 Parkin-EOPD (≤50 years)Cross-sectionalMMSENo significant differences
596 LRRK2-EOPD, GBA-EOPD, and noncarriers
Lohmann et al. [65]21 Parkin-EOPD (<45 years)Cross-sectionalMMSE, MDRS, Grober and Buschke test, WCST, TMT, FABNo significant differences
23 EOPD noncarriers
9 asymptomatic Parkin carriers
Caccappolo et al. [66]43 Parkin-EOPD (≤50 years)Cross-sectionalNeuropsychological batteryNo significant differences
52 EOPD noncarriers
217 controls (146 noncarriers and 71 asymptomatic Parkin carriers)
CORE-PD cohort
Alcalay et al. [67]21 Parkin-EOPD (≤50 years) and long duration disease (>14 years)Cross-sectionalNeuropsychological batteryParkin-PD performed better on tests of attention, memory, and visuospatial cognitive domains
23 EOPD noncarriers
CORE-PD cohort
Tan et al. [33]9 Parkin-EOPD (≤50 years)Cross-sectionalMoCAParkin-PD performed better
202 EOPD noncarriers

EOPD = early-onset Parkinson’s disease; MMSE = Mini-Mental State Examination; MDRS = Mattis Dementia Rating Scale; WCST = Wisconsin card sorting test; TMT = trail-making test; FAB = frontal assessment battery.